Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

3(42.9%)

7Total

Phase 2(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05933070Phase 1Terminated

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Role: lead

NCT05318976Phase 2Completed

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Role: lead

NCT06056791Phase 1Completed

Study of INKmune in Patients With mCRPC (CaRe Prostate)

Role: lead

NCT05522387Phase 2Terminated

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Role: lead

NCT05321498Phase 2Withdrawn

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Role: lead

NCT03943264Phase 1Completed

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

Role: lead

NCT04370236Phase 2Terminated

INB03 for the Treatment of Pulmonary Complications From COVID-19

Role: lead

All 7 trials loaded